Alzheimer’s and Covid-19 developers make hay on the stock markets
Big risers include Eli Lilly, Biogen, Moderna and Biontech.
Why Glaxo should buy Biohaven
And four other potential targets that could make sense for the beleaguered group.
Big pharma leads the way in stock market resurgence
And Lilly was well ahead of the pack, fuelled by Alzheimer’s hopes.
Curevac’s credibility unravels along with its Covid-19 vaccine
Long-awaited results from the Herald study are a bust, and the data will likely deteriorate further.
Novavax's Prevent-19 lives up to its name
But with many Western markets already saturated, it is worth wondering how important Novavax’s Covid-19 jab will become.
Covid-19 vaccine leaders make hay while Novavax flounders
Instead of long-awaited phase 3 data Novavax’s first-quarter presentation reveals a Covid-19 vaccine manufacturing snafu.
